Armata Pharmaceuticals, Inc.

ARMP Healthcare Biotechnology

Armata Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, down 5.22% from fiscal 2024. In the quarter to June 2026, revenue grew 15.7%, EPS grew 548.9%, free cash flow fell 18.0% and total debt rose 152.4%, each against the same quarter a year earlier.

3.37 0.28 +9.06%
Market cap
$114.9M
P/E
0.0×
Fwd P/E
−2.0×
Dividend yield
—
F-score
3/9
Altman Z
−10.15
Beneish M
−12.48
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

64.00% 130.37% 154.70% 127.83%
Piotroski F-Score
1 2 3 —
ROA
(49.96%) (212.83%) (359.90%) (225.11%)
ROIC
(57.94%) (77.26%) (87.61%) (89.61%)
Return on Tangible Assets
42.46% (1,249.00%) (3,325.65%) 90.73%
Average Days of Receivables
54.82 35.13 3.30 166.73
Free Cash Flow per Share
(0.76) (0.73) (0.67) (0.70)
Free Cash Flow
(27.43) (26.30) (24.47) (25.79)
Other line items

Show all line items

Columns are period end dates